Ascendis Pharma (NasdaqGS:ASND) is back in focus after new Week 52 data from its reACHin trial showed once weekly TransCon CNP helped stabilize foramen magnum stenosis and supported linear growth in infants with achondroplasia.

Recent news around Ascendis Pharma has arrived against a backdrop of firm upward momentum, with a 90 day share price return of 20.85% and a year to date share price gain of 7.39% suggesting interest has been building rather than fading. The latest Week 52 reACHin data sits alongside a fresh Canadian reimbursement recommendation for YORVIPATH and a global settlement with BioMarin that clears key patent disputes. Together, these developments help frame the current US$263.52 share price as a reflection of both perceived growth potential in rare disease endocrinology and a shift in how investors view the legal and execution risks around its TransCon portfolio.

Capitalize on the momentum around Ascendis Pharma by scanning a curated 31 high quality undervalued stocks, which may offer similar rare disease exposure with stronger value signals.

For Ascendis Pharma, a 21% move over 90 days could reflect solid execution in rare disease endocrinology or simply a shift in overall risk sentiment. The current valuation analysis now has to separate the underlying story from the market price.

Most Popular Narrative: 15.9% Undervalued

Ascendis Pharma's most followed narrative points to a fair value of $313.36 against a last close of $263.52, which frames the recent rally as only part of the story.

Expansion of SKYTROFA into additional established growth hormone indications such as ISS, SHOX deficiency, Turner syndrome and SGA, alongside potential use in new segments like achondroplasia, can increase total addressable demand and contribute to higher revenue and more efficient use of existing commercial infrastructure.

Read the complete narrative.

Want to see what kind of revenue trajectory and margin profile that expansion story assumes? The narrative leans on rapid top line compounding, hefty profitability and a richer future earnings multiple that is above the broader biotech sector.

Result: Fair Value of $313.36 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the bullish Ascendis Pharma story can break if YORVIPATH uptake plateaus or if TransCon CNP approvals, labels, or adoption fall short of current expectations.

Find out about the key risks to this Ascendis Pharma narrative.

Next Steps

Mixed signals so far from Ascendis Pharma, with clear upside potential alongside concerns that investors are watching closely. Act quickly and form your own view by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Ascendis Pharma?

Do not stop with a single story like Ascendis Pharma when the wider market still holds plenty of overlooked opportunities that could suit your style and risk comfort.

• Target potential value plays by scanning a curated pool of underpriced businesses through the 31 high quality undervalued stocks and compare how their current tags stack up against fundamentals.
• Strengthen portfolio resilience by focusing on companies with healthier finances using the list of solid balance sheet and fundamentals (23 results) before market stress puts weaker balance sheets under pressure.
• Spot early-stage potential by reviewing the 16 high quality undiscovered gems and see which underfollowed stocks align with your return expectations and risk limits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.